- Home
- TZUP vs CNTX Comparison
TZUP vs CNTX Comparison
Compare TZUP & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TZUP
- CNTX
- Stock Information
- Founded
- TZUP 2020
- CNTX 2015
- Country
- TZUP United States
- CNTX United States
- Employees
- TZUP N/A
- CNTX N/A
- Industry
- TZUP
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- TZUP
- CNTX Health Care
- Exchange
- TZUP NYSE
- CNTX Nasdaq
- Market Cap
- TZUP 66.7M
- CNTX 78.0M
- IPO Year
- TZUP N/A
- CNTX 2021
- Fundamental
- Price
- TZUP $12.67
- CNTX $0.73
- Analyst Decision
- TZUP
- CNTX Strong Buy
- Analyst Count
- TZUP 0
- CNTX 5
- Target Price
- TZUP N/A
- CNTX $5.50
- AVG Volume (30 Days)
- TZUP 376.1K
- CNTX 152.6K
- Earning Date
- TZUP 08-11-2025
- CNTX 08-06-2025
- Dividend Yield
- TZUP N/A
- CNTX N/A
- EPS Growth
- TZUP N/A
- CNTX N/A
- EPS
- TZUP N/A
- CNTX N/A
- Revenue
- TZUP $487.00
- CNTX N/A
- Revenue This Year
- TZUP N/A
- CNTX N/A
- Revenue Next Year
- TZUP N/A
- CNTX N/A
- P/E Ratio
- TZUP N/A
- CNTX N/A
- Revenue Growth
- TZUP N/A
- CNTX N/A
- 52 Week Low
- TZUP $2.02
- CNTX $0.49
- 52 Week High
- TZUP $13.44
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- TZUP N/A
- CNTX 63.77
- Support Level
- TZUP N/A
- CNTX $0.62
- Resistance Level
- TZUP N/A
- CNTX $0.67
- Average True Range (ATR)
- TZUP 0.00
- CNTX 0.05
- MACD
- TZUP 0.00
- CNTX 0.01
- Stochastic Oscillator
- TZUP 0.00
- CNTX 90.63
About TZUP THUMZUP MEDIA CORP
Thumzup Media Corp operates in the social media branding and marketing industry. The company operates in a single business segment which is social media marketing. The Thumzup App works on both iPhone and Android mobile operating systems and connects brands and people who use and love these brands. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through Venmo and PayPal.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.